TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00770575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and atorvastatin
Description: Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:~Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to~Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.
Study: NCT00107640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-provider education
Description: Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
Study: NCT02809716

Intervention type: OTHER
Intervention: Biomarker Analysis
Description: Correlative studies
Study: NCT03884465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled dry powder treprostinil (LIQ861)
Description: Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.
Study: NCT02809716

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and tissue samples
Study: NCT02447224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 gm IV ertapenem at enrollment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 gm IV ertapenem at enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Study: NCT02720107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod
Study: NCT02649348

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: pre-operative prehabilitation
Description: To climb six flights of stairs (approximately 20 meters in height) at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction (increased thoracic and decreased abdominal breathing compliance) following abdominal surgery by using a full elastic breathable abdominal bandage.
Study: NCT00748852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-302
Description: JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
Study: NCT01677429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR movie + balance challenge
Description: Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: still pictures from VR
Description: Monitoring only still pictures from the VR scene in a loop, no balance challenge

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: For the treatment of panic disorder
Study: NCT03719534

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: haplo-HCT
Description: HCT will be performed with a haploidentical donor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haplo-cord HCT
Description: Haploidentical donor HCT will be performed with coinfusion of unrelated cord blood unit
Study: NCT02300636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Co-contraction training at 60 knee flexion angle by using leg press machine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Standard ACL rehabilitation
Study: NCT02672696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluoroMap 3D
Description: Use of the 3D reconstruction software developed by the manufacturer of the Gamma Nail (e.g. Stryker Inc.) along with the standard fluoroscopy
Study: NCT04468529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Neuregulin for injection
Description: 10 hours per day i.v. drip for the first 10 days (0.6ug/kg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 hours per day i.v. drip for the first 10 days (0ug/kg/day)
Study: NCT03459391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221 60 mg
Description: The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221 200 mg
Description: The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
Study: NCT01945710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin-LF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin-LF
Study: NCT01771809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75mg SHP647 (PF-00547659)
Description: 75 mg sterile liquid injected subcutaneously every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225mg SHP647 (PF-00547659)
Description: 225 mg sterile liquid injected subcutaneously every 4 weeks.
Study: NCT03800394

Intervention type: OTHER
Intervention: Observational PK study
Description: Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations

Intervention type: OTHER
Intervention: Observational PK study
Description: Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
Study: NCT02856191

Intervention type: OTHER
Group type: OTHER
Intervention: Holter
Study: NCT01800175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Punctum Plug

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Punctum Plug
Study: NCT00727441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreatic cancer vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreatic cancer vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreatic cancer vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV (Arm B), given orally (Arm C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV (Arm B), given orally (Arm C)
Study: NCT03038477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
Study: NCT04992702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animated Video
Description: Animated video to improve learning and motivation
Study: NCT04140032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level preschool obesity control intervention
Description: The multi-level intervention is a preschool-based program that integrates healthy nutrition and physical activity policies and practices into preschool operations via the Sesame Street Healthy Habits for Life curriculum. In addition to the curriculum, the intervention includes coaching sessions to enhance teacher lesson planning to routinely include nutrition and physical activity; as well as assist preschool site directors with implementing policy changes and parent engagement sessions.
Study: NCT04313647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1X level of MSCs-Exo
Description: Once aerosol inhalation of MSCs-derived exosomes (2.0\*10\^8 nano vesicles/3 ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2X level of MSCs-Exo
Description: Once aerosol inhalation of MSCs-derived exosomes (4.0\*10\^8 nano vesicles/3 ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4X level of MSCs-Exo
Description: Once aerosol inhalation of MSCs-derived exosomes (8.0\*10\^8 nano vesicles/3 ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6X level of MSCs-Exo
Description: Once aerosol inhalation of MSCs-derived exosomes (12.0\*10\^8 nano vesicles/3 ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8X level of MSCs-Exo
Description: Once aerosol inhalation of MSCs-derived exosomes (16.0\*10\^8 nano vesicles/3 ml)
Study: NCT04992702

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Animated Video
Description: Animated video to improve learning and motivation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animated Video
Description: Animated video to improve learning and motivation
Study: NCT04124744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Champions intervention
Description: Health Champions are trained volunteers who will support service users with their physical health goals over 9 months, meeting once a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group-treatment as usual
Description: Participants will receive treatment as usual from their Community Mental Health Team
Study: NCT03939013

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert HCV VL
Description: Use of Cepheid GeneXpert HCV VL test as diagnostic tool to test for HCV RNA for diagnosis of hepatitis C infection, to test for sustained virological response at 12 weeks post treatment completion
Study: NCT00256295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 IV over 100 minutes Every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days
Study: NCT02027129

Intervention type: OTHER
Group type: OTHER
Intervention: High Frequency Oscillation
Description: Comparison of low frequency HFO/HFO-TGI with cuff leak and high frequency HFO without cuff leak on right ventricular function
Study: NCT02176746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cancer stem cell vaccine
Study: NCT03663556

Intervention type: OTHER
Intervention: Infant-feeding
Description: Preterm infants hospitalized in the NICU can be feed by three different types of infant feeding, such as breast milk, donor human milk and/or formulas.
Study: NCT00940667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Losartan
Description: amlodipine/losartan 5/50mg q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: amlodipine 5mg q.d.
Study: NCT02811627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: The subjects will undergo an MRI assessment after baseline behavioral assessment. The session will involve a structural MRI scan, single voxel spectroscopy scans and resting state functional MRI. The subjects will be started on memantine post the imaging session. The imaging will be carried out on a research dedicated 3 Tesla (3T) Siemens Trio Scanner at the University of Missouri Brain Imaging Center by trained personnel.
Study: NCT02110602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet high in amino acid levels
Description: Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet high in amino acid levels
Description: Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet low in amino acid levels
Description: Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet low in amino acid levels
Description: Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
Study: NCT05090176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: povidone-soaked suture
Description: suture soak with povidone solution for 3 mins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ordinary suture
Description: suture no need to soak with povidone solution
Study: NCT00849316

Intervention type: DRUG
Intervention: insulin aspart
Description: Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
Study: NCT00754221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: Once a day, oral treatment, of 4, 6, 8 or 10 mg
Study: NCT04143308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous training of walking and cognitive group
Description: Device:~1. SWATCH system (App \& controller)~2. Wearable technology Fitness wristband \& APP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training group
Description: Device:~1. SWATCH system (App)~2. Wearable technology Fitness wristband \& APP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual group
Description: Keep treatment as usual
Study: NCT01957670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrima medical Prototypes
Study: NCT04545970

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Facial cleanser
Description: Facial cleanser to be used by study participants

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Facial cleanser
Description: Facial cleanser to be used by study participants

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Facial moisturizer
Description: Bland moisturizer to be used by study participants after serum in the evening.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Facial moisturizer
Description: Bland moisturizer to be used by study participants after serum in the evening.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of serum in the morning.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of serum in the morning.
Study: NCT04544215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dosage 1 of MPCs-derived exosomes
Description: 7 times aerosol inhalation of MPCs-derived exosomes (8.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dosage 2 of MPCs-derived exosomes
Description: 7 times aerosol inhalation of MPCs-derived exosomes (16.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: No MPCs-derived exosomes
Description: No aerosol inhalation of MPCs-derived exosomes
Study: NCT01357811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat; digoxin
Description: repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: digoxin
Description: oral 0.25mg dose of digoxin (single dose) on Day 1
Study: NCT02369081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment for 12 weeks.
Study: NCT06190457

Intervention type: OTHER
Intervention: intrathecal rituximab
Description: All children were treated with a modified NHL-BFM95 regimen for children NHL with the addition of rituximab, both intravenous and intrathecal, and rituximab intrathecal infusion is scheduled to be used simultaneously with rituximab intravenous drip. rituximab intrathecal doses are 10 mg, 15 mg, and 20 mg in increments every 3 weeks. rituximab intrathecal injection does not use methotrexate or/and cytarabine intrathecaline chemotherapy.
Study: NCT02680353

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral superficial cervical plexus block
Description: A kind of anesthetic nerve block type performed to block the nerve function temporarily by administrating local anesthetics through the trajectory of the nerve.
Study: NCT01112709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCT-based Resistance Training exercise program
Description: Two supervised RT sessions per week for the first 3 months, then a self-monitored RT phase for the remainder of the study, with primarily Internet-based contact.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intervention with minimal contact
Description: This is the control condition for comparison; the approach will be identical to the experimental condition, but without the theoretical components (skills to increase self efficacy for RT, self regulation for RT). Contact with the study staff will be reduced from that received by the experimental group.
Study: NCT00741819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Study: NCT00948220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a and ribavirin
Description: standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
Study: NCT02930980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Software loaded on Micra device
Description: Subject will receive an investigational software loaded on subject's Micra device
Study: NCT04582123

Intervention type: PROCEDURE
Group type: OTHER
Intervention: crossed pin configuration
Description: comparison of two crossed pin fixation methods
Study: NCT03869801

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: Ultrasound-guided bilateral Erector spinae plane (ESP) block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quadratus lumborum block
Description: Ultrasound-guided bilateral Quadratus lumborum (QLB) type 2 block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
Study: NCT03470532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buccal infiltration of 4% Articaine with Epinephrine
Description: Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buccal infiltration of 2% Mepivacaine with Epinephrine
Description: Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge
Study: NCT00917215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable stainless steel acupuncture (0.2mmx4mm)
Description: For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.~For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Disposable stainless steel acupuncture (0.2mmx4mm)
Description: For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.~For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks.
Study: NCT00409331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: 500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity- Modulated Radiation Therapy
Description: 2.0 to 2.2 Gy delivered in 30 fractions
Study: NCT01464957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-tailored newsletter
Description: Delivered over 3 consecutive years, in the spring